In order to develop a personalized approach to preventing side effects of statins, a clinical (in vivo) and experimental (in vitro) study of 60 patients with coronary heart disease was conducted. The comparison group (n = 30) received basic therapy (atorvastatin 20 mg/day). The main group (n = 30) additionally received the etoxidol cytoprotector. Atorvastatin monotherapy was found to cause a significant increase in markers of myopathy and myocardial cytolysis (total creatine phosphokinase CPK, MB-CPK, myoglobin) with a moderate hypolipidemic effect. In the etoxidol group, the levels of these markers decreased. The in vitro study showed that the cytoprotective activity of etoxidol was maximum in cases of hypercholesterolemia (CH > 6.6 mmol/l), and that of trimetazidine – in cases of normal/low CH (< 5.3 mmol/l). Personalized prescription of a cytoprotector depending on the level of total blood cholesterol is proposed as a new method for preventing the side effects of statin therapy.